Supernus Pharmaceuticals ( (SUPN) ) has provided an update.
On February 19 and 20, 2025, Supernus Pharmaceuticals’ Board of Directors approved modifications to the compensation packages of its executive officers following recommendations from the Compensation Committee. The changes, effective January 1, 2025, include salary increases and stock options for executives like Timothy C. Dec, Padmanabh P. Bhatt, Jonathan Rubin, Frank Mottola, and CEO Jack A. Khattar. These adjustments align with industry standards and were advised by Aon plc, reflecting the company’s commitment to competitive compensation practices.
More about Supernus Pharmaceuticals
Supernus Pharmaceuticals operates in the pharmaceutical industry, focusing on developing and commercializing products for the treatment of central nervous system diseases.
YTD Price Performance: -9.28%
Average Trading Volume: 399,391
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.82B
For detailed information about SUPN stock, go to TipRanks’ Stock Analysis page.